Ipsen

Ipsen is a French pharmaceutical company that agreed in July 2026 to acquire Swiss rare-disease biotech Memo Therapeutics for up to €700 million. Memo is developing potravitug, a Phase II antibody against BK polyomavirus infection in kidney-transplant patients — a deal that illustrates how Swiss biotech's exit path increasingly runs through acquisition by larger European pharma rather than an IPO.